PARK CITY, Utah--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced they will be hosting two virtual R&D Investor calls for analysts and investors focused on the Company’s ...

It has been about a month since the last earnings report for Arena Pharmaceuticals, Inc. (ARNA). Shares have lost about 2.8% in that time frame, underperforming the S&P 500. Will the recent negative ...

- ISS ESG Corporate Rating uses comprehensive research and data to allow institutional investors to identify Environmental, Social and Governance (ESG) risks and seize investment opportunities - ...

Well Fargo upgraded Arena to Outperform. Price target is $53. Analyst sees large pharma interest as very possible. Investors in Arena Pharmaceuticals (ARNA) had a good day on January 3rd. The equity ...

Arena Pharmaceuticals, Inc. (ARNA) came out with a quarterly loss of $2.40 per share versus the Zacks Consensus Estimate of a loss of $2.21. This compares to loss of $1.61 per share a year ago. These ...

Arena Pharmaceuticals, based in San Diego, Cal., is a biotech company with one segment of its drug pipeline dedicated to cannabinoid-type therapeutics. The core of its cannabis biotech operations is ...

PARK CITY, Utah--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE - The Pfizer logo is displayed at the company's headquarters, Feb. 5, 2021, in New York. Pfizer is spending $6.7 billion to ...

Pfizer Inc.’s presentation of its pending $6.7 billion acquisition of clinical-stage drug company Arena Pharmaceuticals Inc. contained no mention of cannabis. But it turns out that one of several ...

Multinational pharmaceutical and biotechnology firm Pfizer, Inc. (PFE) has signed an agreement to acquire California-based biopharmaceutical company Arena Pharmaceuticals, Inc. (ARNA) for ...